Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to ...

Align Technology (NASDAQ:ALGN) been upgraded to outperform from market perform by Leerink Partners. Calling Align ...

Leerink Partnrs upgraded shares of Align Technology (NASDAQ:ALGN – Free Report) from a hold rating to a strong-buy rating in a research note released on Monday morning,Zacks.com reports. ALGN has been ...

Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Geron in a note issued ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...

CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...

Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a ...

(Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of ...

Leerink analyst Daina Graybosch downgraded Lava Therapeutics (LVTX) to Market Perform from Outperform with a price target of $2, down from $11, following the company’s discontinuation of LAVA ...

https://www.tipranks.com/news/the-fly/iteos-therapeutics-price-target-lowered-to-19-from-31-at-wells-fargo Leerink analyst Christopher Liu lowered the firm’s price ...

Leerink upgraded Align Technology (ALGN) to Outperform from Market Perform with a price target of $280, up from $235. For what remains a clear ...